Related Experiment Videos

SCEDOSPORIUM INFECTION IN A PATIENT WITH ANTI-TNFα THERAPY

Caroline T Nguyen1, Siba P Raychaudhuri

  • 1Department of Medicine, VA Medical Center Sacramento and UC Davis School of Medicine, Division of Rheumatology, Allergy and Clinical Immunology , Hospital Way, Mather, CA 95655, USA.

Indian Journal of Dermatology
|May 17, 2011
PubMed

Insights

Patients on anti-tumor necrosis factor alpha (anti-TNFα) therapy face higher risks of rare infections. This case highlights Scedosporium apiospermum infection in an anti-TNFα treated patient, emphasizing the need for vigilance against atypical infections in immunocompromised individuals.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Rheumatology

Background:

  • Anti-tumor necrosis factor alpha (anti-TNFα) therapy is widely used for inflammatory conditions.
  • Patients receiving anti-TNFα therapy are known to have an increased susceptibility to opportunistic infections.
  • Rare fungal infections can pose significant challenges in immunocompromised patients.

Purpose of the Study:

  • To report a rare case of Scedosporium apiospermum infection in a patient undergoing long-term anti-TNFα therapy.
  • To raise awareness among clinicians about the risk of atypical infections in patients treated with anti-TNFα agents.
  • To emphasize the importance of vigilant monitoring for opportunistic pathogens in this patient population.

Main Methods:

  • Case report detailing a patient's clinical presentation, diagnosis, and management.
  • Review of relevant literature on Scedosporium apiospermum infections and anti-TNFα therapy.
  • Clinical observation and microbiological investigation.

Main Results:

  • A patient on anti-TNFα therapy for five years developed a Scedosporium apiospermum infection.
  • The infection presented as an atypical opportunistic infection in an immunocompromised host.
  • Prompt recognition and management are crucial for favorable outcomes.

Conclusions:

  • Anti-TNFα therapy can predispose patients to rare and severe opportunistic infections like Scedosporium apiospermum.
  • Clinicians must maintain a high index of suspicion for atypical infections in patients on anti-TNFα therapy.
  • Close patient follow-up and prompt diagnostic workup are essential for managing immunocompromised patients.
Keywords:
Scedosporiumanti-TNF therapyimmunocompromised

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...